Gro Gausdal

BerGenBio (Norway) — Norway

Immunology and Microbiology · Life Sciences

20h-index1.2kcitations104works2.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Phagocytosis and Immune Regulation(66), Pancreatic and Hepatic Oncology Research(36), Cancer Immunotherapy and Biomarkers(20), Hippo pathway signaling and YAP/TAZ(12), Cancer Mechanisms and Therapy(11)

Publications104 total

Supplementary Figure from Mutated HRAS Activates YAP1–AXL Signaling to Drive Metastasis of Head and Neck Cancer
2025Open Access
Supplementary Data from Mutated HRAS Activates YAP1–AXL Signaling to Drive Metastasis of Head and Neck Cancer
2025Open Access
AXL Kinase Inhibition Promotes Cytosolic DNA Sensor cGAS Activity and Sensitizes Poorly Immunogenic Tumors to Chemo-Immunotherapy
Molecular Cancer Therapeutics·2025
AXL-TBK1 driven AKT3 activation promotes metastasis
Science Signaling·2024· 5 citedOpen Access
Targeting AXL cellular networks in kidney fibrosis
Frontiers in Immunology·2024· 5 citedOpen Access
Supplementary Data from Mutated HRAS activates YAP1-AXL signaling to drive metastasis of head and neck cancer
2024Open Access
Supplementary Figure from Mutated HRAS activates YAP1-AXL signaling to drive metastasis of head and neck cancer
2024Open Access
Supplementary Data from Mutated HRAS activates YAP1-AXL signaling to drive metastasis of head and neck cancer
2024Open Access
Supplementary Figure from Mutated HRAS activates YAP1-AXL signaling to drive metastasis of head and neck cancer
2024Open Access
Data from Mutated HRAS activates YAP1-AXL signaling to drive metastasis of head and neck cancer
2024Open Access
In vivo turnover and biodistribution of soluble AXL: implications for biomarker development
Scientific Reports·2024· 3 citedOpen Access
Dynamic changes in immune cell populations by AXL kinase targeting diminish liver inflammation and fibrosis in experimental MASH
Frontiers in Immunology·2024· 13 citedOpen Access
598 Bemcentinib + pembrolizumab show promising efficacy in metastatic NSCLC harbouring mutations associated with poor prognosis: exploratory sub-analysis from the BGBC008 trial (NCT03184571)
Regular and Young Investigator Award Abstracts·2023Open Access
Supplementary Table S1 from AXL Targeting Overcomes Human Lung Cancer Cell Resistance to NK- and CTL-Mediated Cytotoxicity
2023Open Access
Supplementary Table S2 from AXL Targeting Overcomes Human Lung Cancer Cell Resistance to NK- and CTL-Mediated Cytotoxicity
2023Open Access
Supplementary Data from AXL Targeting Overcomes Human Lung Cancer Cell Resistance to NK- and CTL-Mediated Cytotoxicity
2023Open Access
Supplementary Data from Mutated HRAS Activates YAP1–AXL Signaling to Drive Metastasis of Head and Neck Cancer
2023· 1 citedOpen Access
Supplementary Figure from Mutated HRAS Activates YAP1–AXL Signaling to Drive Metastasis of Head and Neck Cancer
2023Open Access
Supplementary Table S1 from AXL Targeting Overcomes Human Lung Cancer Cell Resistance to NK- and CTL-Mediated Cytotoxicity
2023Open Access
Data from Mutated HRAS Activates YAP1–AXL Signaling to Drive Metastasis of Head and Neck Cancer
2023Open Access
page 1 of 6Next →

Frequent Co-authors

James B. Lorens(29), David Micklem(15), Rolf A. Brekken(14), Magnus Blø(14), Stein Ove Døskeland(13), Bjørn Tore Gjertsen(11), Katarzyna Wnuk-Lipińska(10), Agnete S. T. Engelsen(8), Lavina Ahmed(8), Lars Herfindal(8), Oddbjørn Straume(8), John D. Minna(7), Øystein Bruserud(7), Linn Hodneland(7), Monica Hellesøy(6), Jean Paul Thiery(6), Salem Chouaı̈b(6), Hans‐Peter Marti(6), Sébastien Bougnaud(6), Kjersti Davidsen(6)